SCHEMBL16654196

SCHEMBL16654196

CC(N)CC(=O)N1CCN(C)CC1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.46
CYP1A2 P05177 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
POLB P06746 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
DPP4 P27487 2/20 0.43
CYP2C19 P33261 1/20 0.40
MAPT P10636 1/20 0.39
HSD17B10 Q99714 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
KDM4C Q9H3R0 1/20 0.39
CACNA2D1 P54289 1/20 0.38
CACNA1B Q00975 1/20 0.38
CACNB1 Q02641 1/20 0.38
CACNA1C Q13936 1/20 0.38
CYP3A4 P08684 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22248833 1.00 HTR1A (0.46) HTR1ACYP1A2TDP1POLBNPSR1
SCHEMBL2625513 0.83 POLB (0.61) HTR1ACYP1A2TDP1POLBNPSR1
SCHEMBL14738409 0.83 ATM (0.46) CYP1A2TDP1POLBNPSR1L3MBTL1
SCHEMBL10265713 0.83 ATM (0.46) CYP1A2TDP1POLBNPSR1L3MBTL1
SCHEMBL12583677 0.82 HTR1A (0.47) HTR1ACYP1A2TDP1POLBNPSR1
SCHEMBL4323039 0.82 L3MBTL1 (0.46) TDP1POLBNPSR1L3MBTL1DPP4
Hydrochloric Acid SCHEMBL15124306 0.82 ATM (0.45) CYP1A2TDP1POLBNPSR1L3MBTL1
SCHEMBL13383340 0.82 HTR1A (0.47) HTR1ACYP1A2TDP1POLBNPSR1
SCHEMBL12583610 0.82 HTR1A (0.47) HTR1ACYP1A2TDP1POLBNPSR1
SCHEMBL1768361 0.81 CYP1A2 (0.42) HTR1ACYP1A2TDP1POLBNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3057943-A1 PYRIMIDINE FGFR4 INHIBITORS Eisai R&D Management Co., Ltd. (JP) 2016-08-24 EP claimed
WO-2015057938-A1 PYRIMIDINE FGFR4 INHIBITORS EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-23 WO claimed
EP-3796900-B1 TRITERPENE AMINE DERIVATIVES DFH THERAPEUTICS (US) 2026-04-08 EP disclosed
US-11236122-B2 Triterpene amine derivatives DFH THERAPEUTICS (US) 2022-02-01 US disclosed
US-20210253627-A1 TRITERPENE AMINE DERIVATIVES THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2021-08-19 US disclosed
EP-3796900-A1 TRITERPENE AMINE DERIVATIVES DFH Therapeutics (US) 2021-03-31 EP disclosed
EP-3057943-A1 PYRIMIDINE FGFR4 INHIBITORS Eisai R&D Management Co., Ltd. (JP) 2016-08-24 EP disclosed
WO-2015057938-A1 PYRIMIDINE FGFR4 INHIBITORS EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210253627-A1 TRITERPENE AMINE DERIVATIVES BET1, PGGT1B, NFATC1 HTR1A 792/4885CYP1A2 962/4885TDP1 1420/4885
US-11236122-B2 Triterpene amine derivatives BET1, PGGT1B, NFATC1 HTR1A 792/4885CYP1A2 962/4885TDP1 1420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.